» Articles » PMID: 37460726

Molecular Imaging for Early-Stage Disease Diagnosis

Overview
Date 2023 Jul 17
PMID 37460726
Authors
Affiliations
Soon will be listed here.
Abstract

With the development of cellular biology, molecular biology, and other subjects, targeted molecular probe was combined with medical imaging technologies to launch a new scientific discipline of molecular imaging that is a research discipline to visualize, characterize, and analyze biological process at the cellular and molecular levels for real-time tracking and precision therapy, also termed as the medical imaging in the twenty-first century. An array of imaging techniques has been developed to image specific targets of living cells or tissues by molecular probes, including optical molecular imaging (OI), magnetic resonance molecular imaging, ultrasound (US) molecular imaging, nuclear medicine molecular imaging, X-ray molecular imaging, and multi-mode molecular imaging. These imaging techniques make the early diagnosis of various diseases possible by means of visualization of gene expression, interactions between proteins, signal transduction, cell metabolism, cell traces, and other physiological or pathological processes in the living system, which bridge the gap between molecular biology and clinical medicine. This chapter will lay the emphasis on the early-stage diagnosis of fatal diseases, such as malignant tumors, cardio- or cerebrovascular diseases, digestive system disease, central nervous system disease, and other diseases employing molecular imaging in a real-time visualized manner.

Citing Articles

Visualizing the Tumor Microenvironment: Molecular Imaging Probes Target Extracellular Matrix, Vascular Networks, and Immunosuppressive Cells.

Chan H, Kuo D, Shueng P, Chuang H Pharmaceuticals (Basel). 2025; 17(12.

PMID: 39770505 PMC: 11676442. DOI: 10.3390/ph17121663.

References
1.
Lu J, Liong M, Li Z, Zink J, Tamanoi F . Biocompatibility, biodistribution, and drug-delivery efficiency of mesoporous silica nanoparticles for cancer therapy in animals. Small. 2010; 6(16):1794-805. PMC: 2952648. DOI: 10.1002/smll.201000538. View

2.
Pal S, Ray A, Andreou C, Zhou Y, Rakshit T, Wlodarczyk M . DNA-enabled rational design of fluorescence-Raman bimodal nanoprobes for cancer imaging and therapy. Nat Commun. 2019; 10(1):1926. PMC: 6486596. DOI: 10.1038/s41467-019-09173-2. View

3.
Xiong L, Chen Z, Yu M, Li F, Liu C, Huang C . Synthesis, characterization, and in vivo targeted imaging of amine-functionalized rare-earth up-converting nanophosphors. Biomaterials. 2009; 30(29):5592-600. DOI: 10.1016/j.biomaterials.2009.06.015. View

4.
Xiong L, Chen Z, Tian Q, Cao T, Xu C, Li F . High contrast upconversion luminescence targeted imaging in vivo using peptide-labeled nanophosphors. Anal Chem. 2009; 81(21):8687-94. DOI: 10.1021/ac901960d. View

5.
Wang M, Mi C, Wang W, Liu C, Wu Y, Xu Z . Immunolabeling and NIR-excited fluorescent imaging of HeLa cells by using NaYF(4):Yb,Er upconversion nanoparticles. ACS Nano. 2009; 3(6):1580-6. DOI: 10.1021/nn900491j. View